Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …

Tissue stiffness has long been known to be a biomarker of tissue pathology. Ultrasound
elastography measures tissue mechanical properties by monitoring the response of tissue to …

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …

Quantitative imaging biomarkers of liver disease measured by using MRI and US are
emerging as important clinical tools in the management of patients with chronic liver disease …

Liver MR elastography is an imaging technique used to measure liver stiffness in the
evaluation for possible fibrosis or cirrhosis. Liver stiffness measurement (LSM) is useful for …

Hepatic fibrosis is potentially reversible; however early diagnosis is necessary for treatment
in order to halt progression to cirrhosis and development of complications including portal …

Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis,
as the last stage of numerous chronic liver diseases, is one of the most relevant prognostic …

Purpose To compare liver stiffness measurements obtained from MR elastography with liver
T1 relaxation times obtained from T1 mapping and T2 relaxation times obtained from T2 …

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease, with a worldwide
prevalence of 25%. NAFLD is a spectrum that includes nonalcoholic fatty liver defined …

Liver fibrosis is a histological hallmark of most chronic liver diseases, which can progress to
cirrhosis and liver failure, and predisposes to hepatocellular carcinoma. Accurate diagnosis …